• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    2/14/23 3:44:21 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    SC 13G/A 1 esta.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Establishment Labs Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ X ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G31249108 13G Page 2 of 7 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Investments, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,002,767* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,002,767* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,002,767* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.12%** 12. TYPE OF REPORTING PERSON (see instructions) IA CUSIP No. G31249108 13G Page 3 of 7 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Efrem Kamen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,002,767* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,002,767* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,002,767* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.12%** 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. G31249108 13G Page 4 of 7 Pages Item 1. (a) Name of Issuer Establishment Labs Holdings Inc. (b) Address of Issuers Principal Executive Offices Building B15 and 25, Coyol Free Zone, Alajuela, Costa Rica Item 2. (a) Name of Person Filing Pura Vida Investments, LLC Efrem Kamen (collectively, the "Filers"). (b) The address of the principal place of the Filers is located at: Pura Vida Investments, LLC 512 West 22nd Street, 7th Floor, New York, NY 10022 (c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer. (d) Title of Class of Securities Common Stock (e) CUSIP Number G31249108 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1) (ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1) (ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). CUSIP No. G31249108 13G Page 5 of 7 Pages Item 4. Ownership. (a) Amount beneficially owned: Pura Vida Investments LLC 1,002,767* shares Efrem Kamen 1,002,767* shares (b) Percent of class: Pura Vida Investments LLC 4.12%** Efrem Kamen 4.12%** (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote Pura Vida Investments LLC 1,002,767* shares Efrem Kamen 1,002,767* shares (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of Pura Vida Investments, LLC 1,002,767* shares Efrem Kamen 1,002,767* shares *Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. Efrem Kamen serves as the managing member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Pura Vida Master Fund and the Managed Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein. **The percentages herein are calculated based upon 24,342,327 shares of Common Stock of the Issuer outstanding per the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 8, 2022. Item 5. Ownership of Five Percent or Less of a Class. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A CUSIP No. G31249108 13G Page 6 of 7 Pages Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2023 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member CUSIP No. G31249108 13G Page 7 of 7 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Pura Vida Investments, LLC. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G. Dated: February 14, 2023 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member
    Get the next $ESTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    10/13/2022$70.00Buy
    Mizuho
    8/24/2022$107.00Buy
    B. Riley Securities
    11/10/2021$88.00 → $90.00Overweight
    Stephens & Co.
    More analyst ratings

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 12:54:20 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 9:03:38 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

      SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      2/14/24 4:51:40 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces CEO Transition

      Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

      1/13/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat

      5/1/24 8:30:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel and CCO Mansbach Samuel Ross was granted 7,952 shares, increasing direct ownership by 109% to 15,238 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:50:37 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Chief Financial Officer Denhoy Raj was granted 11,200 shares, increasing direct ownership by 92% to 23,348 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:49:52 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Int Chief Executive Officer Caldini Filippo was granted 17,231 shares, increasing direct ownership by 207% to 25,539 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:48:39 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Lewin Nicholas Sheridan bought $54,073 worth of shares (2,000 units at $27.04), increasing direct ownership by 0.19% to 1,064,888 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      12/15/23 7:59:37 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Lewin Nicholas Sheridan bought $110,000 worth of shares (5,000 units at $22.00) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/21/23 8:00:55 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Denhoy Raj bought $49,972 worth of shares (2,250 units at $22.21), increasing direct ownership by 38% to 8,112 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/20/23 8:00:42 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Financials

    Live finance-specific insights

    See more
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and launched in U.S.; Motiva U.S. revenue in the fourth quarter of $3.3 million. Fourth quarter net loss from operations of $18.7 million, a 15% reduction compared to a net loss of $22.1 million in the year-ago period. F

      2/26/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Establishment Labs

      Needham initiated coverage of Establishment Labs with a rating of Hold

      4/14/25 7:48:56 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs downgraded by Citigroup with a new price target

      Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00

      5/22/24 7:26:41 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Establishment Labs with a new price target

      JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00

      8/31/23 7:13:36 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Establishment Labs Holdings Inc.

      10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/9/25 4:01:46 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Establishment Labs Holdings Inc.

      DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:05:26 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:04:12 PM ET
      $ESTA
      Industrial Specialties
      Health Care